Institut für klinische Forschung Pneumologie

The Institut für klinische Forschung Pneumologie in Frankfurt is conducting respiratory research focused on asthma, with studies aimed at improving symptom control, lung function, and overall treatment effectiveness in people whose disease remains difficult to manage.

• Severe and inadequately controlled asthma
• Mild to moderate asthma
• Evaluating new inhaled treatment options for better breathing outcomes

These trials explore whether newer inhaler-based therapies can help reduce exacerbations and improve day-to-day respiratory stability for patients with persistent asthma symptoms.

The site is also involved in infectious disease research, including studies in COVID-19 for people at higher risk of becoming seriously ill. This work focuses on finding treatments that may help prevent disease worsening in nonhospitalized patients.

• COVID-19 at high risk of progression to severe illness
• Testing an antiviral approach against placebo
• Supporting early treatment strategies for viral illness

By examining treatment effectiveness early in the course of infection, the research aims to improve outcomes for vulnerable patients before hospitalization becomes necessary.

Another key area of research at this health care site centers on comparing established asthma therapies and assessing whether different inhaled formulations perform similarly in patients with controlled or partly controlled disease.

• Comparing inhaled therapies for mild to moderate asthma
• Measuring changes in lung function
• Evaluating therapeutic equivalence of new inhaler formulations

This line of research helps determine whether alternative inhaled medicines can provide comparable respiratory benefits while maintaining effective control of symptoms.